	US 12,486,178 B2
	Copper nanoclusters, composition comprising the same, and treatment of multiple sclerosis
Taolei Sun, Wuhan (CN)
Assigned to Shenzhen Profound-View Pharma Tech Co., Ltd, Shenzhen (CN)
Filed by Shenzhen Profound-View Pharma Tech Co., Ltd, Shenzhen (CN)
Filed on Jun. 28, 2024, as Appl. No. 18/757,727.
Application 18/757,727 is a division of application No. 17/309,744, granted, now 12,060,281, previously published as PCT/CN2019/093463, filed on Jun. 28, 2019.
Prior Publication US 2024/0391792 A1, Nov. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/61 (2017.01); A61K 9/14 (2006.01); A61K 33/34 (2006.01); A61K 47/54 (2017.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); C01G 3/00 (2006.01); C08L 5/08 (2006.01); B82Y 5/00 (2011.01); B82Y 30/00 (2011.01); B82Y 40/00 (2011.01)

CPC C01G 3/006 (2013.01) [A61K 9/14 (2013.01); A61K 33/34 (2013.01); A61K 47/54 (2017.08); A61K 47/542 (2017.08); A61K 47/545 (2017.08); A61K 47/61 (2017.08); A61K 47/64 (2017.08); A61K 47/6923 (2017.08); A61P 25/16 (2018.01); A61P 25/28 (2018.01); C08L 5/08 (2013.01); B82Y 5/00 (2013.01); B82Y 30/00 (2013.01); B82Y 40/00 (2013.01); C01P 2004/04 (2013.01); C01P 2004/64 (2013.01)]

10 Claims

1. A pharmaceutical composition for treating multiple sclerosis in a subject, said pharmaceutical composition comprising:

copper nanoclusters; and

a pharmaceutically acceptable excipient;

wherein said copper nanoclusters comprise a ligand; and

wherein the ligand-modified copper nanoclusters have a diameter in the range of 0.5-5 nm.